Ozempic and Mitochondria

GLP-1 medications like Ozempic are being widely prescribed, with over 20 million prescriptions last year, yet they serve primarily as appetite suppressants without addressing the underlying issues of mitochondrial dysfunction. The high cost of these medications raises questions about their long-term efficacy, especially since many users regain weight after discontinuation. The conversation highlights the need for a deeper understanding of how our environment impacts health, rather than relying solely on pharmaceutical solutions.